A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018

被引：0
|
作者：
Damian, Fernanda Bronzon
De Melo, Andreia Cristina
Dal Molin, Graziela Zibetti
Rodrigues, Angelica Nogueira
de Carvalho Calabrich, Aknar Freire
Werutsky, Gustavo
Abdo Filho, Elias
Rebelatto, Taiane Francieli
de Jesus, Rafaela Gomes
Jimenez, Mirela Foresti
机构：
[1] Hosp Sao Lucas PUCRS, Porto Alegre, Brazil
[2] Grp Hosp Conceicao, Hosp Femina, Porto Alegre, Brazil
[3] Brazilian Gynecol Oncol Grp EVA, Belo Horizonte, Brazil
[4] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, Brazil
[5] Brazilian Natl Canc Inst INCA, Div Clin Res & Technol Dev, Rio De Janeiro, Brazil
[6] Benefencia Portuguesa Sao Paulo, Sao Paulo, Brazil
[7] Univ Fed Minas Gerais UFMG, Belo Horizonte, Brazil
[8] AMO, Salvador, Brazil
[9] Inst Canc Estado Sao Paulo ICESP, Sao Paulo, Brazil
[10] Univ Fed Ciencias Saude Porto Alegre UFCS, Porto Alegre, Brazil
[11] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Saude Ginecol & Obstet, Porto Alegre, RS, Brazil
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5514
引用
收藏
页数：1
相关论文
共 14 条
  • [1] PALBOCICLIB PLUS LETROZOLE COMBINATION AFTER PROGRESSION ON SECOND-LINE CHEMOTHERAPY FOR WOMEN WITH ER/PR-POSITIVE HIGH-GRADE SEROUS OR ENDOMETRIOID OVARIAN, FALLOPIAN TUBE OR PERITONEAL CANCER (LACOG 1018)
    Damian, Fernanda
    Zibetti Dal Molin, Graziela
    Rodrigues, Angelica
    De Carvalho Calabrich, Aknar
    Werutsky, Gustavo
    Filho, Elias Abdo
    Jimenez, Mirela Foresti
    Rebelatto, Taiane
    De Jesus, Rafaela
    Cristina De Melo, Andreia
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A243 - A243
  • [2] Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Ray-Coquard, Isabelle
    Braicu, Ioana
    Berger, Regina
    Mahner, Sven
    Sehouli, Jalid
    Zeimet, Alain G.
    lauraine, Eric Pujade
    Cassier, Philippe Alexandre
    Moll, Utemartha
    Ulmer, Hanno
    Leunen, Karin
    Marth, Christian
    Vergote, Ignace
    Concin, Nicole
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Concin, Nicole
    Braicu, Loana
    Berger, Regina
    Mahner, Sven
    Sehouli, Jalid
    Zeimet, Alain G.
    Pujade-Lauraine, Eric
    Cassier, Philippe Alexandre
    Moll, Ute Martha
    Ulmer, Hanno
    Leunen, Karin
    Marth, Christian
    Vergote, Ignace
    Ray-Coquard, Isabelle Laure
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women with high-grade serous, high-grade endometrioid, or undifferentiated, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Concin, Nicole
    Braicu, Ioana
    Combe, Pierre
    Ray-Coquard, Isabelle Laure
    Joly, Florence
    Harter, Philipp
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] A phase 2, open-label study of niraparib in women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer after ≥3 previous chemotherapy regimens.
    Moore, Kathleen N.
    Rimel, Bj
    Agarwal, Shefali
    Balser, John
    Martell, Robert E.
    Monk, Bradley J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE)
    de la Rosa, Consuelo Nohpal
    Krell, Jonathan
    Day, Emily
    Clarke, Aaron
    Reddi, Meena
    Webber, Lee
    Fiorentino, Francesca
    TRIALS, 2022, 23 (01)
  • [7] Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE)
    Consuelo Nóhpal de la Rosa
    Jonathan Krell
    Emily Day
    Aaron Clarke
    Meena Reddi
    Lee Webber
    Francesca Fiorentino
    Trials, 23
  • [8] VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC)
    Coleman, R. L.
    Fleming, G. F.
    Brady, M. F.
    Swisher, E.
    Steffensen, K. D.
    Friedlander, M.
    Okamoto, A.
    Moore, K.
    Ben-Baruch, N.
    Werner, T. L.
    Oaknin, A.
    Nam, J-H.
    Leath, C. A., III
    Nicum, S.
    Cella, D.
    Sullivan, D. M.
    Ansell, P. J.
    Dinh, M.
    Aghajanian, C.
    Bookman, M. A.
    ANNALS OF ONCOLOGY, 2019, 30 : 895 - 896
  • [9] Real world study on the effect of PARPi as maintenance therapy after first-line and second-line chemotherapy on platinum sensitivity in patients with recurrent high-grade serous epithelial ovarian cancer.
    Guo, Yanglong
    Zhang, Yingli
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer
    Guo, Yanglong
    Chen, Xi
    Tang, Xuedong
    Pan, Shan
    Zhu, Tao
    Zhang, Yingli
    CURRENT CANCER DRUG TARGETS, 2024, 24 (07) : 733 - 748
12